

## **Advancing the Cardiovascular Care of the Oncology Patient** 11 - 12, 2022



### PRE-CONFERENCE SESSIONS

(Recordings from 2021 Advancing the Cardiovascular Care of the Oncology Patient)

101 Essentials: Overview of Pharmacology for Cardio-Oncology

Christine Cambareri, PharmD, BCPS, BCOP Mitchell Hughes, PharmD, BCPS, BCOP

**Immune Therapy 101 and Cardiovascular Risk** 

Tom Neilan, MD, MPH, FACC

**All About Amyloidosis** 

Ron Witteles, MD, FACC Michaela Liedtke, MD

AL and ATTR Amyloidosis: Diagnostic and Management Fundamentals for the Cardiologist and Oncologist

Ron Witteles, MD, FACC Michaela Liedtke, MD

FRIDAY.	, febr	<b>UARY</b>	11
---------	--------	-------------	----

	<b>Welcome and Introductions</b>
10:00 a.m.	Ana Barac, MD, PhD, FACC
	Bonnie Ky, MD, MSCE, FACC

#### Session I: How to Strengthen Our Cardio-Oncology Community for Our Patients

	Plenary
10:15 a.m.	Building Bridges in Cardio-Oncology: How to Improve Outcomes in Cancer Patients and Survivors
	Lidia Schapira, MD

#### Session II: Cardio-Oncology Essentials: Pharmacology and Imaging

10:45 a.m.	201 Essentials: Overview of Pharmacology for Cardio-Oncology*  Christine Cambareri, PharmD, BCPS, BCOP  David Reeves, PharmD, BCOP
11:30 a.m.	Cardiac Imaging and Functional Testing: Which Test, When, Why, and How?  Moderators: Ana Barac, MD, PhD, FACC and Bonnie Ky, MD, MSCE, FACC  Presenters: Daniel Addison, MD; Jessica Scott, PhD; Dinesh Thavendiranathan, MD, MSc; and Sujethra Vasu, MD
12:30 p.m.	Break

#### Session III: Cardiovascular Disease Across the Entire Cancer Spectrum: How to Monitor, Mitigate, and Modify Risk

	Breast Cancer and Risk of Cardiovascular Disease: The Landscape of Neoadjuvant, Adjuvant, and Metastatic Treatment
1:00 p.m.	Ann Partridge, MD, MPH
	Josh Mitchell, MD, FACC

<sup>\*</sup> Pre-Conference session available On Demand in early February





FRIDAY, FEBRUARY 11 Continued	
1:50 p.m.	How to Manage Cardiovascular Disease Risk with Prostate Cancer and Androgen Deprivation Therapy  Darryl Leong, MBBS  Alicia Morgans, MD
2:30 p.m.	Heme Malignancies and Stem Cell Transplantation: The Short- and Longer-Term Cardiovascular Risks Betty Hamilton, MD Michael Fradley, MD
3:30 p.m.	Break
4:00 p.m.	What are the Risks of Cardiovascular Disease with Lung Cancer?  Lova Sun, MD, MSCE  Ray Mak, MD
4:40 p.m.	Immune Therapy and Cardiovascular Risk: What Do We Know and Where Does the Field Need to Go?*  Tom Neilan, MD, MPH, FACC  Kerry Reynolds, MD
5:50 p.m.	Pearls from Day 1 Ana Barac, MD, PhD, FACC Bonnie Ky, MD, MSCE, FACC
6:00 p.m.	Adjourn

SATURDAY	SATURDAY, FEBRUARY 12		
10:00 a.m.	Welcome and Introductions  Ana Barac, MD, PhD, FACC  Bonnie Ky, MD, MSCE, FACC		
Session IV: H	Session IV: How to Manage Cardiovascular Risk in Our Cancer Patients: Best Practices and Latest Science		
10:15 a.m.	How to Manage Hypertension in Cancer Patients and Survivors: Which Targets, Which Meds and Which Populations?  Ray Townsend, MD  Moderators: Ana Barac, MD, PhD, FACC and Bonnie Ky, MD, MSCE, FACC  Case Presenters: Atul Chugh, MBBS, FACC and Kerry Skurka, RN		
11:15 a.m.	Cardioprotection: What Have the Clinical Trials Told Us?  Ariane Macedo, MD		
11:55 a.m.	Break		
12:15 p.m.	The Growing Intersection between CV Disease and Cancer: From Biology to Epidemiology Benjamin Ebert, MD, PhD Rudolf A. de Boer, MD		
1:15 p.m.	Cardiovascular Concerns in AYA and Adult Survivors of Childhood Cancers Greg Armstrong, MD, MSCE		

<sup>\*</sup> Pre-Conference session available On Demand in early February





SATURDAY	SATURDAY, FEBRUARY 12 Continued	
1:45 p.m.	How to Use Biomarkers in Cardio-Oncology: What Does the Evidence Tell Us?  Bonnie Ky, MD, MSCE, FACC	
2:15 p.m.	Break	
Session V: Ho	ow to Build Your Cardio-Oncology Program	
2:30 p.m.	Lunch and Learn How to Build a Cardio-Oncology Training and Clinical Program: Perspectives from Academia and the Community Moderators: Ana Barac, MD, PhD, FACC and Kerry Skurka, RN Panel: Carrie Lenneman, MD, FACC; Vivek Narayan, MD, MSCE; Vijay Rao, MD, PhD, FACC; Diego Sadler, MD, FACC; and Deborah W. Sundlof, DO, FACC	
Session VI: H	ow to Diagnose and Manage Amyloidosis in 2022	
3:30 p.m.	Multiple Myeloma and AL Amyloidosis: 201 Diagnostic and Management Pearls for the Cardiologist and Oncologist*  Ron Witteles, MD, FACC  Michaela Liedtke, MD	
4:10 p.m.	ATTR Amyloidosis: When to Suspect, How to Diagnose and How to Treat*  Ron Witteles, MD, FACC	
Session VII: H	Session VII: How to Achieve Health Equity	
4:50 p.m.	Plenary Health Care Disparities: How Can We Achieve Health Equity? Dipti Itchhaporia, MD, FACC Moderators: Ana Barac, MD, PhD, FACC and Bonnie Ky, MD, MSCE, FACC Panel: Daniel Addison, MD; Mary Branch, MD, MS; and Sherry-Ann Brown, MD, PhD, FACC	
5:30 p.m.	Pearls from Day 2 Ana Barac, MD, PhD, FACC Bonnie Ky, MD, MSCE, FACC	
5:40 p.m.	Adjourn	



# Advancing the Cardiovascular Care of the Oncology Patient VIRTUAL FEBRUARY 11 - 12, 2022



#### **BONUS ON DEMAND CONTENT**

(Recordings from 2021 Advancing the Cardiovascular Care of the Oncology Patient)

#### Fireside Chat - Your Cardio-Oncology Community

Moderators: Ana Barac, MD, PhD, FACC and Bonnie Ky, MD, MSCE, FACC

Panel: Ludhmila Hajjar, MD, PhD; Daniel Lenihan, MD, FACC; Teresa López-Fernández, MD; Charlotte Manisty, MD, PhD, FRCP; and Dinesh Thavendiranathan, MD, MSc

#### Cardiac Imaging and Functional Testing: Which Test, When, Why, and How?

Charlotte Manisty, MD, PhD, FRCP

Dinesh Thavendiranathan, MD, MSc

Eric Yang, MD, FACC

#### Cardio-Oncology Clinical Practice Guidelines: What You Need to Know

Saro Armenian, DO, MPH

Daniel Lenihan, MD, FACC

#### Who is at Cardiovascular Risk in Breast Cancer and How to Manage that Risk

Ana Barac, MD, PhD, FACC

Anne Blaes, MD

#### Tyrosine Kinase Inhibitors: What are the Most Significant Cardiovascular Concerns?

Michael Fradley, MD

Vivek Narayan, MD, MSCE

#### **Defining Who is at Cardiovascular Risk in Hematologic Malignancies**

Saro Armenian, DO, MPH

Eric Yang, MD, FACC

#### The Evolution of Radiation Therapy and Risk of Cardiovascular Disease

David Hodgson, MD, MPH, FRCPC

Anju Nohria, MD, MSc

#### **Bleeding/Thrombosis and Management of Anticoagulation in Cancer Patients**

Mitchell Hughes, PharmD, BCPS, BCOP

Alok Khorana, MD

#### Adult and Pediatric Cancer Survivorship: Management of Modifiable Cardiovascular Risk Factors

Kevin C. Oeffinger, MD

Rachel Barish, NP, AACC

<sup>\*</sup> Pre-Conference session available On Demand in early February